Aaron Waxman, CHEST 2021: Inhaled Treprostinil in Patients with Interstitial Lung Disease and Associated Pulmonary Hypertension
TouchRESPIRATORY were delighted to catch up with Professor Aaron Waxman (Brigham and Women’s Hospital, Boston, MA, USA) to discuss the findings from the dose response analysis of the INCREASE study.
The abstract entitled ‘DOSE RESPONSE ANALYSIS OF INHALED TREPROSTINIL IN PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE AND ITS EFFECTS ON CLINICAL WORSENING.’ was presented at CHEST 2021, 17-20 October 2021.
- Could you give us a brief overview of the occurrence of pulmonary hypertension (PH) in interstitial lung disease (ILD) and its prognostic significance? (0:21)
- What did the INCREASE study teach us about the efficacy and safety of inhaled treprostinil in patients with ILD and associated PH? (1:39)
- What were the aims and design of the current analysis? (2:39)
- What were the dose-response effects on clinical worsening and what are their clinical implications in terms of dose titration? (3:51)
- What were the limitations of this study? (6:07)
Disclosures: Aaron Waxman discloses being an investigator for United Therapeutics, Acceleron, Altavant, Gossamer, and ARIA-CV.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of CHEST 2021 (Virtual).
Share this Video
Related Videos In Pulmonary Hypertension
Jean Elwing, CHEST 2022: Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease – the INCREASE OLE study
INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the […]
Marc Simon, CHEST 2022: Clinical benefits with a higher dose of LIQ861 in pulmonary arterial hypertension – analysis of the LTI-301 clinical trial
INSPIRE (LTI-301 clinical trial) was a phase 3 study investigating the long-term safety and tolerability of LIQ861 in patients with pulmonary arterial hypertension (NCT03399604). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) around the aims, design and eligibility criteria of the LTI-301 clinical trial and the findings from […]
Marc Simon, CHEST 2022: LIQ861 for the treatment of pulmonary arterial hypertension
LIQ861 is an investigational, inhaled dry powder formulation of treprostinil delivered through a device, which currently has tentative approval from the FDA for the treatment of pulmonary arterial hypertension (PAH). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) about LIQ861 and its potential advantages over conventional formulations of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!